What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study
2008

Oncologists' Communication About Palliative Chemotherapy Survival Benefits

Sample size: 37 publication Evidence: moderate

Author Information

Author(s): Audrey Suzanne, Abel Julian, Blazeby Jane M, Falk Stephen, Campbell Rona

Primary Institution: University of Bristol

Hypothesis

How much do oncologists communicate about the survival benefits of palliative chemotherapy during consultations?

Conclusion

Most patients were not given clear information about the survival gain of palliative chemotherapy.

Supporting Evidence

  • 26 out of 37 consultations had vague or no discussion of survival benefit.
  • Only 6 patients received numerical data about survival benefit.
  • Patients often did not ask about survival benefit, leading to less information being shared.

Takeaway

Doctors often don't tell cancer patients how long palliative chemotherapy might help them live, which can make it hard for patients to make informed choices.

Methodology

Qualitative study observing and recording oncology consultations.

Potential Biases

Potential bias due to the presence of a researcher during consultations.

Limitations

The study had a small sample size and may not represent all oncology consultations.

Participant Demographics

37 patients with advanced cancer, including 13 men and 24 women, with various cancer types.

Digital Object Identifier (DOI)

10.1136/bmj.a752

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication